ArticleTranslational cancer research2025
Development and validation of nomograms for predicting the prognosis of colorectal cancer patients.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Integrating prognosis-related genes with immune-related gene signature for development and validation of a survival stratification model for early-stage colorectal cancer.Translational cancer research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Accurate prognosis prediction is essential in colorectal cancer (CRC) for guiding treatment decisions, yet the traditional tumor-node-metastasis (TNM) staging system often lacks precision. This study aimed to develop improved prognostic tools for CRC patients. Methods: Prognostic nomogram models were developed using data from 2,435 CRC patients who underwent curative resection. Parameters were selected via least absolute shrinkage and selection operator (LASSO) regression to include overall survival (OS) and disease-free survival (DFS) nomograms. The performance of these nomograms was evaluated against the TNM staging system using ROC analysis, calibration curves, and decision curve analysis (DCA). Results: Critical prognostic factors identified included tumor invasion depth, distant metastasis, tumordifferentiation grade, extranodal tumor deposits (ENTD), R1 resection, and log odds of positive lymph nodes (LODDS). The OS nomogram demonstrated area under the curve (AUC) values of 0.786, 0.776, and 0.803 for predicting 1-, 3-, and 5-year survival, respectively, compared to 0.768, 0.750, and 0.782 for TNM staging. The DFS nomogram predicted 1-, 3-, and 5-year DFS with AUCs of 0.764, 0.777, and 0.789, respectively, compared to 0.762, 0.761, and 0.770 for TNM staging. Calibration plots indicated strong predictive capabilities, and DCA confirmed greater net benefits over TNM staging. Conclusions: Our developed prognostic nomogram models offer enhanced accuracy over traditional TNM staging in predicting CRC prognosis. Integrating these models into clinical practice can potentially improve personalized treatment strategies for postoperative CRC patients, enhancing overall clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.